Dr. François Marceau has been studying bradykinin receptors for over 30 years, their regulation, ligands and functions. Notably, as early as in the 1980s, the regulation of B1 receptor expression by cytokines and immunopathology was highlighted, with work replicated and expanded around the world. He has been part of an international committee on the nomenclature of bradykinin receptors, leading to a review article cited over 800 times, of which he is a co-author (Pharmacol Rev. 2005; 57: 27). More recently, two subjects have caught the attention of the laboratory, i.e. the creation of bifunctional biotechnological ligands for peptide hormone receptors, including those of bradykinin, and the angioedema states, presently the main clinical application of bradykinin. Dr. Marceau has been, and is, regularly invited as a speaker at specialized conferences.

CHUL
2705, boulevard Laurier
T-1-49
Québec, Québec
Canada G1V 4G2

Latest news

Data not available

192 entries « 1 of 20 »

Marceau F, Bachelard H

A Robust Bioassay of the Human Bradykinin B Receptor that Extends Molecular and Cellular Studies: The Isolated Umbilical Vein.

Journal Article

Pharmaceuticals (Basel), 14 (3), 2021.

Abstract | Links:

Talmadge JE, Marceau F

Covid-19 challenges to immune investigations and therapies.

Journal Article

Int Immunopharmacol, 95 , 2021.

| Links:

Marceau F, Bachelard H, Charest-Morin X, Hebert J, Rivard GE

In Vitro Modeling of Bradykinin-Mediated Angioedema States.

Journal Article

Pharmaceuticals (Basel), 13 (9), 2020.

Abstract | Links:

Marceau F, Rivard GE, Gauthier JM, Binkley KE, Bonnefoy A, Boccon-Gibod I, Bouillet L, Picard M, Levesque G, Elfassy HL, Bachelard H, Hebert J, Bork K

Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants.

Journal Article

Front Med (Lausanne), 7 , 2020.

Abstract | Links:

Lesage A, Gibson C, Marceau F, Ambrosi HD, Saupe J, Katzer W, Loenders B, Charest-Morin X, Knolle J

Pharmacological Profile of a New Small Molecule Bradykinin B Receptor Antagonist.

Journal Article

Front Pharmacol, 11 , 2020.

Abstract | Links:

Marceau F, Bachelard H, Bouthillier J, Fortin JP, Morissette G, Bawolak MT, Charest-Morin X, Gera L

Bradykinin receptors: Agonists, antagonists, expression, signaling, and adaptation to sustained stimulation.

Journal Article

Int Immunopharmacol, 82 , 2020.

Abstract | Links:

Pare G, Vitry J, Marceau F, Vaillancourt M, Winter P, Bachelard H, Naccache PH, Tuszynski JA, Fernandes MJ

The development of a targeted and more potent, anti-Inflammatory derivative of colchicine: Implications for gout.

Journal Article

Biochem Pharmacol, 180 , 2020.

Abstract | Links:

Marceau F, Bachelard H, Rivard GE, Hebert J

Increased fibrinolysis-induced bradykinin formation in hereditary angioedema confirmed using stored plasma and biotechnological inhibitors.

Journal Article

BMC Res Notes, 12 (1), 2019.

Abstract | Links:

Charest-Morin X, Hebert J, Rivard GE, Bonnefoy A, Wagner E, Marceau F

Comparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency.

Journal Article

Front Immunol, 9 , 2018.

Abstract | Links:

Bachelard H, Charest-Morin X, Marceau F

D-Arg-Bradykinin-Arg-Arg, a Latent Vasoactive Bradykinin B Receptor Agonist Metabolically Activated by Carboxypeptidases.

Journal Article

Front Pharmacol, 9 , 2018.

Abstract | Links:

192 entries « 1 of 20 »
Signaler des ajouts ou des modifications

Recently finished projects

  • Caractérisation du système kallikréine-kinines chez les familles de patients atteints d'angio-œdème héréditaire avec niveau normal de " C1-esterase inhibitor", from 2019-05-31 to 2021-03-31
Data provided by the Université Laval research projects registery